Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
55.96
+2.98 (5.62%)
Jul 30, 2026, 4:00 PM EDT - Market closed
Vaxcyte Employees
Vaxcyte had 507 employees as of December 31, 2025. The number of employees increased by 93 or 22.46% compared to the previous year.
Employees
507
Change (1Y)
93
Growth (1Y)
22.46%
Revenue / Employee
n/a
Profits / Employee
-$1,866,927
Market Cap
8.08B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 507 | 93 | 22.46% |
| Dec 31, 2024 | 414 | 160 | 62.99% |
| Dec 31, 2023 | 254 | 96 | 60.76% |
| Dec 31, 2022 | 158 | 69 | 77.53% |
| Dec 31, 2021 | 89 | 31 | 53.45% |
| Dec 31, 2020 | 58 | 15 | 34.88% |
| Dec 31, 2019 | 43 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ImmunityBio | 691 |
| Crinetics Pharmaceuticals | 594 |
| Mirum Pharmaceuticals | 418 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Cogent Biosciences | 258 |
| Kymera Therapeutics | 253 |
PCVX News
- 22 days ago - Vaxcyte to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Vaxcyte Transcript: AGM 2026 - Transcripts
- 2 months ago - Vaxcyte Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Vaxcyte doses first participant in VAX-A1 study - TheFly
- 2 months ago - Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults - GlobeNewsWire
- 2 months ago - Vaxcyte Slides: Corporate presentation - Filings
- 2 months ago - Vaxcyte Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 3 months ago - Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77) - TheFly